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Abstract

The inverse probability weighting (IPW) estimator is widely used to estimate the
treatment effect in observational studies in which patient characteristics might
not be balanced by treatment group. The estimator assumes that treatment assignment, is error-free, but in reality treatment assignment can be measured with
error. This arises in the context of comparative effectiveness research, using administrative data sources in which accurate procedural or billing codes are not
always available. We show the bias introduced to the estimator when using errorprone treatment assignment, and propose an adjusted estimator using a validation
study to eliminate this bias. In simulations, we explore the impact of the misclassified treatment assignment on the estimator, and compare the performance
of our adjusted estimator to an estimate based only on the validation study. We
illustrate our method on a comparative effectiveness study assessing surgical treatments among Medicare beneficiaries, diagnosed with brain tumors. We use linked
SEER-Medicare data as our validation data, and apply our method to Medicare
Part A hospital claims data where treatment is based on ICD9 billing codes, which
do not accurately reflect surgical treatment.
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Abstract
The inverse probability weighting (IPW) estimator is widely used to estimate the treatment effect
in observational studies in which patient characteristics might not be balanced by treatment group.
The estimator assumes that treatment assignment, is error-free, but in reality treatment assignment
can be measured with error. This arises in the context of comparative effectiveness research, using
administrative data sources in which accurate procedural or billing codes are not always available.
We show the bias introduced to the estimator when using error-prone treatment assignment, and
propose an adjusted estimator using a validation study to eliminate this bias. In simulations, we
explore the impact of the misclassified treatment assignment on the estimator, and compare the
performance of our adjusted estimator to an estimate based only on the validation study. We
illustrate our method on a comparative effectiveness study assessing surgical treatments among
Medicare beneficiaries, diagnosed with brain tumors. We use linked SEER-Medicare data as our
validation data, and apply our method to Medicare Part A hospital claims data where treatment
is based on ICD9 billing codes, which do not accurately reflect surgical treatment.
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1

Introduction

There is a lot of interest in estimating causal treatment effects. Ideally, randomized control studies
would be used to study treatment effects, but not always these are feasible due to ethical reasons,
cost, time constraints, and compliance (among other reasons). Observational studies are more
widely available, however, involve some limitations. Since subjects are not randomized by treatment,
their characteristics might not be balanced by treatment group. In order to overcome this limitation,
propensity score based methods have been proposed (Rosenbaum and Rubin, 1983).
The propensity score is defined as the probability that an individual has been assigned to
treatment given their covariates. Various propensity score methods have been introduced including
subclassifying, matching, or weighing individuals by their propensity scores. Rosenbaum and Rubin
(1984) introduce a method that stratifies individuals based on their propensity score, and averages
the treatment effect across strata. Matching individuals by their propensity scores attempts to
create treated and control groups that have similar covariate values. Propensity scores can also be
used to weigh individuals observations (Rosenbaum, 1987). The focus of this work is on the inverse
probability weighting (IPW) estimator, which estimates the treatment effect, by weighing treated
individuals by their inverse propensity score and untreated individuals by the inverse of one minus
their propensity score (Rosenbaum, 2005).
The IPW estimator assumes that treatment assignment is measured without error, but in reality
treatment assignment in observational studies could be measured with error. Treatment assignment
in this context, can be thought of as the exposure variable. Standard techniques adjusting for
measurement error in exposures cannot be applied directly to this setting. Misclassification of
treatment assignment will lead to both error in the exposure variable directly, as well as error
in the propensity score estimates. Previous literature using propensity score methods has largely
focused on measurement error in confounders and missing confounders (McCaffrey and others, 2013;
McCandless and others, 2012; Stürmer and others, 2005; Webb-Vargas and others, 2014).
Measurement error in the treatment assignment has been previously considered by Braun and
others (2014). They focus on likelihood-based methods to estimate the treatment effect, and con-
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sider three propensity score implementations (subclassificaiton, matching, and inverse probability
weighting). Under each of these implementations they describe in detail the impact of the misclassified treatment on the three stages of the analysis (propensity score estimation, propensity score
implementation, and outcome analysis) and propose a likelihood-based approach to adjust for the
misclassification.
In contrast to Braun and others (2014) the focus of this work is on estimating the treatment effect
using the IPW estimator. Babanezhad and others (2010) consider a similar setting of mismeasured
exposures. Using estimating equations they derive the asymptotic bias for the IPW and doubly
robust estimators. This work differs from theirs in three main ways: 1) we do not approach
the problem using estimating equations as they do, instead we look at the estimator directly; 2)
their goal was to estimate the causal effect of a binary exposure, T and for an outcome, Y , they
focused on estimating the expected contrast β ∗ = E(Y1 − Y0 ) (where Y1 = Y when T = 0 and
Y0 = Y when T = 1) based on the marginal structure mean model (Hernán and others, 2002):
E(Yt ) = β ∗ t + α∗ t = 0, 1 where α∗ = E(g(x)) and g(X) is an unknown function of the covariates
X. In contrast, our proposed approach does not use any model and estimates the conditional
effect ∆ = E(Y |T = 1, X) − E(Y |T = 0, X) directly. Thus, while they use a linear model to
relate outcome Y and the exposure T , our theoretical analysis is not restricted to a specific type of
outcome or model, and is therefore applicable to any outcome model.
The motivating data application is previously discussed in Braun and others (2014). Briefly,
our interest is in studying the treatment effect of two types of surgery (resection versus biopsy)
among Medicare beneficiaries diagnosed with malignant neoplasm of brain (brain tumors). We are
able to obtain Medicare Part A Hospital claims data, which is a large data set (41,971 individuals)
containing information on our outcome of interest (1-year mortality), the treatment assignment
(the determination of whether resection or a biopsy was preformed), as well as many confounders
(including age, gender, co-morbidities, etc). However, treatment assignment in this data set, is
based on ICD9 billing codes which are inaccurate. For a subset of individuals (5,463 individuals),
we are able to obtain data from SEER-Medicare, a cancer surveillance database with detailed
clinical information. Treatment assignment based on the procedural codes from SEER-Medicare is

4

http://biostats.bepress.com/harvardbiostat/paper201

assumed to be more accurate, gold-standard (Chawla and others, 2014; Cooper and others, 2000;
Du and others, 2000). The SEER registry data managers review patient clinical charts to ascertain
these sort of differences, and do not use claims data in order to appropriately assign treatment
(biopsy vs. resection) received. The SEER-Medicare is our internal validation study.
Using a validation study, we propose an adjusted IPW estimator to estimate the treatment effect
in the main study. In Section 2 we introduce general notation, and then define the IPW estimator
and proposed adjusted estimator in Section 3. We perform simulations in Section 4, and apply our
method to data application in Section 5. Finally, we summarize the main results in Section 6.

2

General Notation

We use Y to denote the true outcome (ex: binary disease status, a continuous, categorical, or survival outcome), T to denote a true binary treatment (ex: surgical treatment assignment based on
procedural codes from SEER-Medicare), Tep to denote the error-prone binary treatment (ex: surgical assignment based on ICD9 billing codes from Medicare Part A), and X to denote confounders
measured without error (ex: age, co-morbidity, etc).
We assume the main study (ex: Medicare Part A enrollees) consists of i = 1, ..., Nm individuals,
for which we observe Y, Tep and X. We assume the validation study (ex: SEER-Medicare enrollees)
consists of j = 1, ..., Nv individuals, where typically Nv < Nm , for which we observe T, Tep , X and
Y . We define N = Nm + Nv . Note that our work assumes settings of either an internal or external
validation study in which Y is observed.
The true propensity score is modeled by a Generalized Linear Model (GLM) relating T to X,
that is P Strue = E(T |X = x, γ) = g −1 (γ0 + γ1T x), where g is known. Similarly, the error-prone
T
x). Propensity
propensity score is modeled with: P Sep = E(Tep |X = x, γep ) = g −1 (γ0ep + γ1ep

scores estimated from these models will be denoted by P d
Strue and Pd
Sep respectively. To model
the measurement error model, we consider a GLM relating T to Tep and X, that is E(T |Tep , X) =
h−1 (θ0 + θ1 Tep + θ2T X) and let πm|n,X = P (T = n|Tep = m, X) n, m = 0, 1.
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3

IPW Estimator

Our interest is in estimating the true average treatment effect (ATE) on the outcome Y for the
entire population; ∆ = E[Y |T = 1, X]−E[Y |T = 0, X]. ∆ can be estimated from the observed data
under the following three assumptions: 1) (T, Y, X) are measured without error, 2) each individual
has a positive probability of being either treated or untreated: 0 < P (T = 1|X) < 1 for all X,
3) the treatment assignment is ignorable, so that, conditional on X, the potential outcomes are
independent of T : (Y0 , Y1 ) ⊥ T |X (where Y0 is the outcome an individual would have had if he/she
were untreated, and Y1 is the outcome an individual would have had if he/she were treated).

3.1

Gold-Standard IPW Estimator

The IPW estimator gives an estimate of the treatment effect, by weighing treated individuals by
their inverse propensity score and untreated individuals by the inverse of one minus their propensity
score (Lunceford and Davidian, 2004; Rosenbaum, 2005). If the true treatment assignment, T , is
known, the IPW estimator would be:

ˆ IP W
∆
true

= N −1

N
X
k=1

N

X (1 − Tk )Yk
Tk Yk
− N −1
d
d
P
S true,k
1−P
S true,k
k=1

The expected value of this estimator is E(Y1 ) − E(Y0 ) (Lunceford and Davidian, 2004), and thus
it provides an unbiased estimate of the true treatment effect.

3.2

Error-prone IPW Estimator

When the true treatment assignment is unknown in the main study, and only information on the
error-prone treatment assignment, Tep , is available, IPW estimator is error-prone and can be written
as:

ˆ IP W
∆
ep

= N

−1

N
X
Tep,k Yk
k=1

d
P
S ep,k

−N

−1

N
X
(1 − Tep,k )Yk
k=1

d
1−P
S ep,k
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We first show that this estimator is biased, and in the following section propose an approach to
adjust for the bias in the main study using the validation study. We begin by defining Y in terms
of potential outcomes, Y0 the outcome an individual would have had if he/she were untreated,
and Y1 the outcome an individual would have had if he/she were treated. Y can be written
as Y = T Y1 + (1 − T )Y0 . It follows that Tep Y = Tep T Y1 + Tep (1 − T )Y0 and (1 − Tep )Y =
(1 − Tep )T Y1 + (1 − Tep )(1 − T )Y0 .
The expectation of each of the two components of the IPW estimator is taken separately. The
expectation of the first component of the estimator is:

E(

Tep Y
Tep Y
Tep T Y1 + Tep (1 − T )Y0
) = EE(
|Y1 , Y0 , X) = EE(
|Y1 , Y0 , X)
P Sep
P Sep
P Sep
Tep T Y1
Tep (1 − T )Y0
= EE(
|Y1 , X) + EE(
|Y0 , X)
P Sep
P Sep
Y1
Y0
= E(
P (Tep = 1, T = 1|Y1 , X)) + E(
P (Tep = 1, T = 0|Y0 , X))
P Sep
P Sep

Similarly, the expectation of the second component of the estimator is:

E(

(1 − Tep )Y
(1 − Tep )Y
(1 − Tep )T Y1 + (1 − Tep )(1 − T )Y0
) = EE(
|Y1 , Y0 , X) = EE(
|Y1 , Y0 , X)
P Sep
1 − P Sep
1 − P Sep
(1 − Tep )(1 − T )Y0
(1 − Tep )T Y1
|Y1 , X) + EE(
|Y0 , X)
= EE(
1 − P Sep
1 − P Sep
Y1
Y0
= E(
P (Tep = 0, T = 1|Y1 , X)) + E(
P (Tep = 0, T = 0|Y0 , X))
1 − P Sep
1 − P Sep
Thus, overall, the expectation of the error-prone IPW estimator is:
Y0
Y1
P (Tep = 1, T = 1|Y1 , X)) + E(
P (Tep = 1, T = 0|Y0 , X))
P Sep
P Sep
Y1
Y0
− E(
P (Tep = 0, T = 1|Y1 , X)) − E(
P (Tep = 0, T = 0|Y0 , X))
1 − P Sep
1 − P Sep

E(∆IP Wep ) = E(

Under two additional assumptions; 1) that the measurement error model is independent of
outcome; P (T = n|Tep = m, Ym , X) = P (T = n|Tep = m, X), n = 0, 1 m = 0, 1, 2) that the
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error-prone treatment assignment is ignorable, so that, conditional on X, the potential outcomes
are independent of Tep : (Y0 , Y1 ) ⊥ Tep |X. , the expectation of the error-prone IPW estimator in
the main study reduces to:

E(∆IP Wep ) = E(Y1 π1|1,X ) + E(Y0 π0|1,X ) − E(Y1 π1|0,X ) − E(Y0 π0|0,X )

(1)

This estimator is clearly biased, and would be unbiased only when π1|1,X = 1 and π0|0,X = 1,
that is if there is no misclassification. Note, the work considered by Babanezhad and others (2010)
is a special case of Equation 1, under the assumption that E(Y1 −Y0 ) = β ∗ , where β ∗ is the expected
contrast.

3.3

Adjusted IPW Estimator

One proposed approach to eliminate the bias caused by using the error-prone treatment, shown
in Equation (1), involves two steps. First, the division of the first component of the estimator in
Equation (1) by π1|1,X and the second component of the estimator by π0|0,X . The expected value
of this new estimator would be:
Y1 π1|1,X
Y0 π0|1,X
Y1 π1|0,X
Y0 π0|0,X
) + E(
) − E(
) − E(
)
π1|1,X
π1|1,X
π0|0,X
π0|0,X
Y0 π0|1,X
Y1 π1|0,X
= E(Y1 ) + E(
) − E(
) − E(Y0 )
π1|1,X
π0|0,X

E(

This first step is not sufficient to eliminate the bias. Two components, E(

Y0 π0|1,X
π1|1,X )

and E(

Y1 π1|0,X
π0|0,X )

contribute to this remaining bias. The proposed second step involves estimating these two bias
components in the validation data, and subtracting them from the overall estimator.
Thus, the proposed adjusted estimator in the main study can be written as:

ˆ IP W
∆
adj−main

−1
= Nm

Nm
X
i=1

N

m
X
Tep,i Yi
(1 − Tep,i )Yi
−1
− Nm
d
d
P
S ep,i πd
(1 − P
S ep,i )πd
1|1,X
0|0,X

i=1
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− Nv−1

Nv
X
j=1

+ Nv−1

Nv
X
j=1

(1 − Tj )Yj πd
0|1,X
d
1|1,X
(1 − P S true,j ) πd
Tj Yj πd
1|0,X
d
0|0,X
P
S true,j πd

(2)

The expected value of this estimator is E(Y1 ) − E(Y0 ), and thus this estimator is unbiased. The
first two sums in Equation (2) are calculated for the main study, however the measurement error
model π1|1,X and π0|0,X will be estimated in the validation study. Thus, the proposed estimator
relies on the transportability assumption. This is a common assumption in the measurement error
literature assuming that the measurement error model is transportable from the validation study
to the main study.
The overall adjusted IPW estimator for the entire population can be written as:

ˆ IP W
∆
adj

−1
= ω(Nm

Nm
X
i=1

N

m
X
Tep,i Yi
(1 − Tep,i )Yi
−1
− Nm
d
d
P S ep,i πd
(1 − P
S ep,i )πd
1|1,X
0|0,X

i=1

Nv
X
(1 − Tj )Yj πd
Tj Yj πd
0|1,X
1|0,X
−1
−
+ Nv
)
d
d
π
d
π
d
j=1 (1 − P S true,j ) 1|1,X
j=1 P S true,j 0|0,X


Nv
Nv
X
X
T
Y
(1
−
T
)Y
j j
j
j 
+ (1 − ω) Nv−1
− Nv−1
d
d
P
S true,j
1−P
S true,j

Nv−1

Nv
X

j=1

j=1

ˆ IP W
ˆ IP W
= ω∆
+ (1 − ω)∆
adj−main
true−val

(3)

ˆ IP W
where ∆
is the IPW estimator based on the true treatment assignment in the valitrue−val
dation study. One common choice for ω is Nm /N , however, we propose instead to use an ω̂ that
ˆ IP W . Let V1 be the variance of ∆
ˆ IP W
minimizes the variance of ∆
, V2 be the variance
adj
adj−main
√
ˆ IP W
of ∆
, and V12 indicate the covariance of the two estimators (ρ V1 V2 , where ρ is the
true−val
correlation of the two estimators).

ˆ IP W
ˆ IP W
var(ω ∆
+ (1 − ω)∆
) = ω 2 V1 + (1 − ω)2 V2 + 2ω(1 − ω)V12 = Vω
adj−main
true−val

(4)

9

Hosted by The Berkeley Electronic Press

Minimizing Equation 4, we obtain ω̂ =
estimator in Equation 3 with ω̂ =

V2 −V12
V1 +V2 −2V12 .

Vˆ2 −Vˆ12
.
Vˆ1 +Vˆ2 −2Vˆ12

Therefore we propose using the adjusted

Vˆ1 , Vˆ2 , and Vˆ12 are obtained by bootstrapping with

500 bootstrap samples.

4

Simulations

The goal of our simulations is to study the effects of measurement error in the treatment assignment
on the IPW estimator. Performance of our proposed estimator is evaluated by comparing treatment
effect estimates for the validation study, main study, and overall population based on true treatment
assignment (gold standard, Equation (1)), error-prone treatment assignment (naive, Equation (1)),
and the proposed adjusted estimator (Equation (3)).

4.1

Simulation Characteristics

For each simulation scenario we simulated two data sets in a similar manner, one to be used as
the main study and one to be used as validation data. We simulated the main study with Nm
individuals and the validation study with Nv individuals. We generate two continuous confounders
X = (1, X1 , X2 ). Tep was generated as Bernoulli according to the error-prone propensity score
logit(P (Tep = 1|X1 )) = γ0 + γ1 X1 . T was generated as Bernoulli according to the measurement
error model logit(P (T = 1|Tep , X2 )) = η0 + η1 T + η2 X2 . Y was generated as Bernoulli according to
the outcome model logit(P (Y = 1|T, X)) = β0 +β1 T +β2 X2 . β = (β0 , β1 , β2 )T = (−0.3, 10, −0.6)T ,
so that β1 = 10. We consider γ = (γ0 , γ1 )T = (0.5, −0.3)T . For the measurement error model,
we consider η = (η0 , η1 , η2 )T = (0.2, 10, −0.1). In addition, six sample sizes were considered 1)
Nm = 3, 000 and Nv = 1, 500, 2) Nm = 5, 000 and Nv = 1, 000, 3) Nm = 4, 000 and Nv = 1, 000, 4)
Nm = 3, 000 and Nv = 1, 000, 5) Nm = 2, 000 and Nv = 1, 000, and 6) Nm = 2, 000 and Nv = 500,
. After the data was generated, we applied the analysis strategies described in previous sections.
100 repetitions were performed for each scenario. For each of the 100 repetitions, 500 bootstrap
samples were used to obtain estimates of V1 , V2 , and V12 .
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4.2

Simulation Results

Figure 1 evaluates the effects of measurement error using the IPW estimator. We present detailed
results for one sample size combination, Nm = 5, 000 and Nv = 1, 000 (Figure 1), the remaining
results are reported in the Web Appendix (Web Figures 1-5). From left to right, we plot results
based on the validation study, main study, and overall study population. For each study population
we calculate the ATE based on the true treatment assignment (GS), and based on the error-prone
treatment assignment (EP). For the overall study population, we also calculate the ATE based on
the proposed adjustment (Equation 3).
Across all study populations, the ATE is unbiased when using the gold standard treatment
assignment, and biased when using the error-prone treatment assignment. Our main interest is in
two potential estimators, the first using the gold standard based only on the validation study, and
the second is our proposed adjustment using both the main and validation studies (Overall: Adj
in Figure 1). Using the gold standard based only on the validation study, the ATE is unbiased,
and the variance is 0.001331. The proposed adjusted is also unbiased, and the variance reduces to
0.000775. Thus, our proposed adjustment provides a 42% decrease in variance.

5

Data Application

We apply the adjusted estimator proposed in this paper, to determine the treatment effect of
resection versus biopsy on one year mortality for Medicare beneficiaries ages 65 and older, diagnosed
with malignant neoplasm of brain between 1999 and 2007. We use the Medicare dataset as our
main study, and the SEER-Medicare dataset as our internal validation study. We focus on a subset
of the population which had either a resection or biopsy performed. Patients in the SEER-Medicare
dataset are also included in the Medicare Part A dataset, but linkage across sources is unidentifiable,
so we cannot determine the Part A record corresponding to each SEER-Medicare record. For this
reason, we decide to limit the Medicare Part A dataset to individuals diagnosed in even years, and
the SEER-Medicare dataset to individuals diagnosed in odd years, thus ensuring that the same
individual is not included in both datasets. In addition, to make the two study populations more
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comparable, we decide to limit our analysis to patients in Medicare Part A that are in the subset
of states included in SEER-Medicare. We also exclude patients diagnosed with other forms of
cancer, allowing us to more accurately evaluate the effect of this specific treatment on mortality.
The final Medicare Part A dataset used for the analysis consisted of 11,036 patients, and the final
SEER-Medicare consisted of 1,582 patients.
We select confounders with at least 2% prevalence in both cohorts for the analysis. This is
described in detail in Braun and others (2014), and summaries of patient characteristics of the two
cohorts are shown in Table 1 (this table also appears in (Braun and others, 2014)). Error-prone
resection rates are higher in SEER-Medicare compared to Medicare Part A (92.0% vs. 62.8%,
p < 2.2 × 10−16 ), and mortality rates are lower in SEER-Medicare compared to Medicare Part A
(72.6% vs. 81.5%, p < 2.2 × 10−16 ). Patient characteristics across some of the confounders also
differ across the cohorts.
Our proposed adjustment assumes the measurement error model is transportable from the validation study to the main study. We hypothesize that errors in the appropriate coding of neurosurgical biopsy vs. resection may be related to important but subtly distinct definitions of biopsy
vs. subtotal resection within the brain. These differences are likely not the focus of physicians or
administrators handling claims, and thus any erroneous or misclassified ICD-9 codes used for these
two procedures should arise similarly for the Medicare component of the Part A dataset as well
as the SEER-Medicare linkage. Therefore, we believe that this transportability assumption likely
holds since the mechanism driving the error is likely similar in the two populations.

5.1

Data Analysis Results

The measurement error model, E(T |Tep , X) = h−1 (θ0 + θ1 Tep + θ2T X), where h is logit, is estimated
in the SEER-Medicare data. We then apply our correction the Medicare Part A dataset. Results
from this analysis are shown in Table 2. We compare the ATE based on the error-prone IPW
estimator to the proposed adjusted IPW estimator. We see that the ATE stays the same after the
adjustment (from −0.11 95% CI: (−0.12, −0.10) to −0.10 95% CI: (−0.17, −0.03). In addition, we
conducted a sensitivity analysis to assess how sensitive the proposed adjustment is to the trans12

http://biostats.bepress.com/harvardbiostat/paper201

portability assumption. We estimated θ̂ in the SEER-Medicare validation study, and then sampled
100 different samples, θd
sens , from a normal distribution with mean θ̂ and standard deviation equal
to standard error estimates of θ̂ multiplied by one, two, or five. These results are presented in
Table 3 and show when there is small variability in the estimates of θ (standard error estimates of
θ̂ multiplied by one) the adjustment yields similar results, but as variability in θ increases results
quickly become less consistent.

6

Discussion

In this paper we present an approach to adjust for measurement error in treatment assignment in
observational studies. We derive the bias in the IPW estimator, propose an adjusted estimator,
and evaluate the performance of the adjusted estimator in simulations with finite sample sizes.
Simulation studies show that, when we adjust for confounding using IPW, the proposed estimator (defined in Equation (3)) is appropriate and performs as well as the gold standard in terms
of bias. In addition, the proposed estimator provides a variance reduction compared to the naive
approach of using the gold standard based on the validation study only.
The proposed estimator relies on a transportability assumption, which requires careful thought.
In our data application, it is reasonable to assume that the mechanism driving the error is the
same for the two populations, as discussed in Section 5. In our data application we assume that
treatment assignment based on SEER-Medicare is the gold standard, however, surgical treatment
assignment in patients with malignant neoplasm of brain is complex. Surgeons will often decide
whether to perform a more extensive tumor resection vs. only a biopsy, which includes removing
less tumor tissue, only once they are in the operating room, based on nearby critical brain regions.
In addition, the line between these two procedures is often ambiguous, and even among surgeons
performing the same procedure there could be discrepancies in coding. Thus, even the SEERMedicare procedural codes might not be an absolute gold-standard, which is a limitation. However,
these codes do provide more accurate information compared to ICD-9 codes, are the best treatment
assignment variables available and permit an illustration of our methods showing the impact of the
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measurement error adjustment.
The IPW estimator is widely used in the literature. Measurement error in exposure, treatment
assignment, is often ignored (Jurek and others, 2006). This paper proposes a direct approach to
estimate the bias, and eliminate it. It is easy to implement, and can be implemented in a wide
range of scenarios in which validation data is available.
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Figure 1: ATE estimator, across 100 simulations for sample size Nm = 5, 000 and Nv = 1, 000.
GS (Gold Standard) is based on the true treatment assignment. EP (Error Prone) is based on the
error-prone treatment assignment. Adj is based on the error-prone treatment assignment with the
proposed adjusted estimator, with ω̂. V1 , V2 , V12 were estimated based on 500 bootstrap samples
for each simulation. The true ATE is marked in red.
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Table 1: Medicare Part A and SEER-Medicare Population Characteristics

Population Size
1-year mortality events
Error-prone Resection based on ICD9 codes
True Resection based on SEER-Medicare
Age
Female
Dual Eligible
Brain MRI
Head CT
Radiotherapy Inpatient ICD9
Atherosclerosis
Substance Abuse
Hypertension
COPD
Dementia
Trauma
Psychological Disorder
Depression
Seizure Disorder
Asthma
Valvular/Rheumatic Heart Disease
Diabetes
Region: West
Region: Midwest
Region: Northeast
Region: South
Admission Type: Emergency
Admission Type: Urgent
Admission Type: Elective
Admission Source: Clinic
Admission Source: HMO
Admission Source: SNF
Admission Source: Court/Law
Admission Source: Other

Medicare Part A
11,036
8,989 (81.5%)
6,928 (62.8%)
74.77
47.1%
7.4%
9.1%
6.6%
2.9%
20.5%
8.0%
60.0%
12.0%
10.2%
4.2%
3.7%
7.0%
20.4%
3.1%
5.7%
18.0%
15.8%
26.9%
19.3%
28.0%
34.9%
23.5%
41.6%
52.5%
4.0%
10.0%
31.2%
2.3%

SEER-Medicare
1,582
1,148 (72.6%)
1,453 (92.0%)
1,242 (78.5%)
73.67
46.6%
6.1%
15.1%
6.7%
8.2%
14.7%
6.2%
57.7%
9.4%
5.6%
3.1 %
2.8%
5.6%
21.7%
2.3%
4.0%
16.4%
45.3%
15.2%
22.6%
16.8%
33.8%
24.2%
42.0%
51.6%
4.4%
10.0%
31.9%
2.1%

P-value
–
< 2.2 × 10−16
< 2.2 × 10−16
–
8 × 10−12
0.69
0.06
4 × 10−14
0.93
< 2 × 10−16
4 × 10−8
0.01
0.09
0.002
1 × 10−8
0.05
0.06
0.04
0.24
0.08
0.005
0.11
< 2.2 × 10−16
< 2.2 × 10−16
0.002
< 2.2 × 10−16
0.37
0.54
0.74
0.51
0.42
0.96
0.55
0.55

Table 2: ATE of resection vs. biopsy in Medicare Part A/SEER-Medicare Data Application,
Outcome 1-year mortality

SEER/Medicare: true trt
Medicare Part A: ep trt
Medicare Part A: adj

ATE [95% CI]
-0.03 [-0.07, 0.03]
-0.11 [-0.13, -0.10]
-0.10 [-0.17, -0.05]
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Table 3: Sensitivity analysis for estimating ATE of resection vs. biopsy in Medicare Part A Data
Application, Outcome 1-year mortality. After estimating θ̂ in the SEER-Medicare validation study,
100 different samples, θd
sens were sampled from a normal distribution with mean θ̂ and standard
deviation equal to standard error estimates of θ̂ multiplied by one, or two.

Medicare Part A: Adj. σ
Medicare Part A: Adj. ∗2σ

Sensitivity Analysis
ATE [95% CI]
-0.09 [-0.30, 0.12]
0.39 [-2.11, 1.99]
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